Mutation Specific Kinase activity Measurements
Profiling Kinase Conformations
KinCon biolabs is a R&D project of the Institute of Biochemistry at the University of Innsbruck.
We are creating unique biosensors for improved kinase-inhibitor development
Our luciferase based reporter measures drug-driven effects on kinase-activity by reflecting changes of cellular kinase-conformations.
This technology allows reliable profiling of potential kinase-inhibitors under physiological conditions:
- Direct measurement in living cells
- Cancer drug profiling in real-time
- Simple integration of patient mutations for precision medicine
Meet the people working to provide you with new tools to assess kinase drug efficacy.
GROUP LEADER | CEO
Project LEAD | CSO
Catch up with our latest News
We are happy to announce that a study co-authored by all members of the KinCon team has been published in PNAS. In this paper we have systematically evaluated drug efficacies by assessing KinCon reporter dynamics in response to different drugs and patient mutations. Our findings suggest that FDA-approved melanoma inhibitors may have the potential to block non-V600E–mutated BRAF activities also in non–small-cell lung cancers (NSCLC). This work showcases that the KinCon reporter platform can help to enhance the development of novel mutation specific kinase inhibitors.
- Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies
With December 1st we started with the execution of proof-of-concept studies to prove the practical suitability and marketability of our KinCon biosensors to accelerate kinase inhibitor development.
Recent Publications in which the KinCon technology is applied
KinCon biolabs is funded and supported by the University of Innsbruck and the Austrian Research Promotion Agency (FFG)